About: Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review
Creator	Majeed, Azeem Rawaf, David Rawaf, Salman Al-Saffar, Mohammed Alshaikh3, Mashael Dubois, Elizabeth Pelly, Michael Quezada-Yamamoto, Harumi
Source	MedRxiv
abstract	In a search to find effective treatments for COVID-19, chloroquine and hydroxychloroquine have gained attention. We aim to provide evidence to support clinical decision-making regarding medication for the treatment of COVID-19 by carrying out a systematic review of the literature. The electronic databases MEDLINE, EMBASE, Global Health, and HMIC were searched up to April 2020. Eligible study outcomes included: extubation or patient recovery. Relevant data were extracted and analysed by narrative synthesis. Our results included six studies in the review of which four studies were of good or fair quality. All eligible studies included were for coronavirus involving the use of either chloroquine or hydroxychloroquine to treat common symptoms such as fever, cough, shortness of breath and fatigue. Outcomes most commonly reported were improved lung function, viral clearance, and hospital discharge. Strong evidence to support the use of chloroquine and hydroxychloroquine in the treatment of COVID-19 is lacking. Fast track trials are riddled with bias and may not conform to rigorous guidelines which may lead to inadequate data being reported. The use of these drugs in combination with other medications may be useful but without knowing which groups they are suited for and when they may cause more harm than good.
has issue date	2020-05-11(xsd:dateTime)
bibo:doi	10.1101/2020.05.07.20094326
has license	medrxiv
sha1sum (hex)	1dc06b667e18ed178765b80f794ecfffa165e4cb
schema:url	https://doi.org/10.1101/2020.05.07.20094326
resource representing a document's title	Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review
resource representing a document's body	covid:1dc06b667e18ed178765b80f794ecfffa165e4cb#body_text
is schema:about of	named entity 'AIM' named entity 'chloroquine' named entity 'provide' named entity 'chloroquine' named entity 'COVID-19' named entity 'Global Health' named entity 'systematic review' named entity 'hydroxychloroquine' named entity 'human subjects' named entity 'coronavirus' named entity 'preprint' named entity 'infection' named entity 'systematic review' named entity 'EMBASE' named entity 'cohort study' named entity 'plasma' named entity 'chloroquine' named entity 'control group' named entity 'clinical trials' named entity 'COVID-19' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'CC-BY-NC-ND 4.0' named entity 'preprint' named entity 'chloroquine' named entity 'medRxiv' named entity 'hydroxychloroquine' named entity 'Zotero' named entity 'clinical characteristics' named entity 'HCQ' named entity 'tazobactam' named entity 'coronavirus' named entity 'chloroquine' named entity 'COVID' named entity 'compromised liver function' named entity 'peer review' named entity 'neuropsychiatric' named entity 'peer review' named entity 'preprint' named entity 'cough' named entity 'medRxiv' named entity 'medRxiv' named entity 'animal studies' named entity 'controlled clinical trials' named entity 'antiviral activity' named entity '2019-nCoV' named entity 'plasma half-life' named entity 'azithromycin' named entity 'ITU' named entity 'Italian' named entity 'virological' named entity 'medRxiv' named entity 'chloroquine' named entity 'coronavirus' named entity 'Severe Acute Respiratory Syndrome' named entity 'chloroquine' named entity 'Meta-Analysis' named entity 'hydroxychloroquine' named entity 'antibiotic therapy' named entity 'Ovid' named entity 'preprint' named entity 'medRxiv' named entity 'hydroxychloroquine' named entity 'respiratory symptoms' named entity 'remission' named entity 'medRxiv' named entity 'Coronaviruses' named entity 'leukopenia' named entity 'lopinavir/ritonavir' named entity 'SARS' named entity 'type 2 diabetes' named entity 'COVID' named entity 'azithromycin' named entity 'systematic reviews' named entity 'risk factors' named entity 'reference manager' named entity 'randomised trials' named entity 'coronavirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software